Can-Fite BioPharma (CANF) Short-term Investments (2017 - 2025)

Can-Fite BioPharma (CANF) has 9 years of Short-term Investments data on file, last reported at $3.0 million in Q4 2025.

• Quarterly Short-term Investments fell 1.5% year-over-year to $3.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.0 million (down 1.5% YoY) and the FY2025 annual result came in at $3.0 million, down 1.5% from the prior year.
• Short-term Investments climbed to $3.0 million in Q4 2025, from $2000.0 in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $14.5 million in Q4 2021 to a low of $2000.0 in Q2 2025.
• A 5-year average of $2.2 million and a median of $29000.0 in 2022 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2021 — Short-term Investments surged 19249.33% — and 2022, when it sank 99.94%.
• Tracing CANF's Short-term Investments over 5 years: stood at $14.5 million in 2021, then slumped by 99.94% to $8000.0 in 2022, then jumped by 137.5% to $19000.0 in 2023, then jumped by 15989.47% to $3.1 million in 2024, then dropped by 1.5% to $3.0 million in 2025.
• The last three Short-term Investments figures came in at $3.0 million (Q4 2025), $2000.0 (Q2 2025), and $3.1 million (Q4 2024), per Business Quant data.